AMENDMENT NO. 2 TO THE PHASE I/IB COMBINATION STUDY AGREEMENTCombination Study Agreement • March 9th, 2020 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS AMENDMENT NO. 2 TO THE PHASE I/IB COMBINATION STUDY AGREEMENT (this “Amendment”) dated as of August 1, 2019 amends the Phase I/IB Combination Study Agreement (the “Agreement”), made and entered into as of October 5, 2015, between Corvus Pharmaceuticals, Inc., having a principal office located at 863 Mitten Road, Suite 102, Burlingame, CA 94010 (“Corvus”), and Genentech, Inc., having a principal office located at 1 DNA Way, South San Francisco, CA 94080.
EXCLUSIVE LICENSE AGREEMENT BETWEEN CORVUS PHARMACEUTICALS, INC. AND MONASH UNIVERSITYExclusive License Agreement • March 9th, 2020 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Exclusive License Agreement (“Agreement”) is effective April 21, 2017 (“Effective Date”), by and between [MONASH UNIVERSITY ABN 12 377 614 012 of Wellington Road, Clayton 3800, in the State of Victoria, Australia] (“Monash”) and Corvus Pharmaceuticals, Inc., a Delaware corporation having a principal place of business at 863 Mitten Road, Suite 102, Burlingame, CA, 94010, USA (“Licensee”) (each a “Party” and jointly the “Parties”) . The Parties agree as follows:
AMENDMENT NO. 1 TO THE PHASE I/IB COMBINATION STUDY AGREEMENTStudy Agreement • March 9th, 2020 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS AMENDMENT NO. 1 TO THE PHASE I/IB COMBINATION STUDY AGREEMENT (this “Amendment”) dated as of December 20, 2017 amends the Phase I/IB Combination Study Agreement (the “Agreement”), made and entered into as of October 5, 2015, between Corvus Pharmaceuticals, Inc., having a principal office located at 863 Mitten Road, Suite 102, Burlingame, CA 94010 (“Corvus”), and Genentech, Inc., having a principal office located at 1 DNA Way, South San Francisco, CA 94080.
AMENDMENT NO. 1 TO THE PHASE IB/II COMBINATION STUDY AGREEMENTStudy Agreement • March 9th, 2020 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS AMENDMENT NO. 1 TO THE PHASE IB/II COMBINATION STUDY AGREEMENT (this “Amendment”) dated as of December 20, 2017 amends the Phase IB/II Combination Study Agreement (the “Agreement”), made and entered into as of May 1, 2017, between Corvus Pharmaceuticals, Inc., having a principal office located at 863 Mitten Road, Suite 102, Burlingame, CA 94010 (“Corvus”), and Genentech, Inc., having a principal office located at 1 DNA Way, South San Francisco, CA 94080.
